Thromboinflammation in LVAD implantation

Principal investigator(s):


Advanced end-stage-heart failure is a serious condition with a high rate of death and hospitalization. Until the last couple of years, heart transplantation has been the single option of treatment. A limited supply of organs challenges heart transplantation, so implantation of a mechanical pump, i.e., a left ventricular assist device (LVAD), has become a life-saving option to bridge patients to transplantation or serve life-long permanent support.

Implantation of a medical device (i.e., a biomaterial) into human tissue is inevitably associated with inflammatory and thrombotic reactions against the non-self component, and the LVAD is a biomaterial prone to activate thromboinflammation; thromboembolism and bleeding are among the frequent and severe complications to LVAD-treatment. Here, we aim to address early thromboinflammatory complications in patients subjected to LVAD-implantation. Early identification of both thrombus, bleeding, and inflammation after device implantation is of high clinical value.

The objective is to study these events in two separate arms:

  1. In a clinical study to evaluate the acute thrombotic and inflammatory response in patients subjected to LVAD-implantation.
  2. In an ex vivo experimental model, target central components of the innate immune system to lower the thromboinflammatory response.


Chaban, Viktoriia Chief medical laboratory technologist
Schjalm, Camilla Chief medical laboratory technologist
Mollnes, Tom Eirik Professor at University of Oslo
Pischke, Søren Professor/Senior Consultant Deputy Oslo